In­no­va­tive prod­ucts for chronic breath­ing ail­ments

Prod­ucts for chronic breath­ing ail­ments

BioSpectrum (Asia) - - Bio Contents -

en­vi­ron­men­tal con­di­tions pre­vent man from breath­ing freely. In­no­va­tors are seen turn­ing their at­ten­tion to the in­creas­ing Copd cases to in­vent in­no­va­tive prod­ucts and so­lu­tions.

Chronic res­pi­ra­tory dis­eases that af­fect the air­ways and dif­fer­ent struc­tures of the lungs are on the rise. As per an ar­ti­cle in the jour­nal Of­fice of Dis­ease Pre­ven­tion and Health Pro­mo­tion, preva­lence of asthma has been in­creas­ing since 1980. Fur­ther­more, Chronic Ob­struc­tive Pul­monary Dis­ease (COPD) is be­lieved to be the fourth main cause of death in North Amer­ica. In 2006, about 1,20,000 peo­ple suc­cumbed to COPD in the United States. This fig­ure was close to the num­ber of pa­tients who lost their battle against lung can­cer. Last year, Jack­son, Mis­sis­sippi was de­clared as the “Al­lergy Cap­i­tal” of the United States by ex­perts in “Asthma and Al­lergy Foun­da­tion of Amer­ica”. Re­searchers at Al­lied Mar­ket Re­search analysing the share, size and growth in the COPD and asthma de­vices mar­ket say con­cerns over air pol­lu­tion will open new av­enues for the in­dus­try.

Im­por­tant pri­or­i­ties to en­hance early di­ag­no­sis

Big brands bank on bil­lion dol­lar in­haler in­dus­try A ma­jor an­nounce­ment in the in­haler in­dus­try ar­rived when El­der Phar­ma­ceu­ti­cals Lim­ited re­vealed that it is bank­ing on the Rs 800 crore nasal in­haler cat­e­gory in In­dia. This pharma com­pany plans on strength­en­ing its ru­ral mar­ket­ing plans and sell­ing prod­ucts through a strong dis­tri­bu­tion chan­nel. Re­duced price points as well as at­trac­tive pack­ag­ing are be­lieved to be some of the ar­eas where in­haler man­u­fac­tur­ers would be fo­cus­ing more.

A com­pany named Teva made waves in the COPD and

asthma de­vices mar­ket when it an­nounced that the Food and Drug As­so­ci­a­tion has fi­nally ac­cepted to re­view the man­u­fac­turer’s new drug ap­pli­ca­tions for two new prod­ucts. The first, a sal­me­terol prod­uct, is Teva’s fixed­dose com­bi­na­tion ICS and LABA, which are de­liv­ered through the com­pany’s Re­spiClick breath-ac­tu­ated, MDPI. An­other flu­ti­ca­s­one pro­pi­onate, which is an ICS monother­apy de­liv­ered through the Re­spiClick de­vice, has also caught quite some at­ten­tion.

Cour­tesy: health.cleve­land­

New pro­to­type neb­u­liser would soon re­place in­jec­tions

Ne­bu­lis­ers are not new. Med­i­cal prac­ti­tion­ers have been us­ing bulky and big elec­tric ne­bu­lis­ers for the past 25 years to help kids’ breathe with­out dif­fi­culty dur­ing an asthma at­tack. How­ever, an ad­vanced pro­to­type neb­u­liser de­vel­oped in 2015 at the fa­mous RMIT, Mel­bourne, has rev­o­lu­tionised the COPD and asthma de­vices mar­ket. De­signed to eas­ily fit into a hu­man hand, the de­vice can de­liver a higher dose of drugs per minute than the cur­rent ne­bu­lis­ers avail­able in the mar­ket. Prod­uct de­vel­op­ers be­hind this ad­vanced de­vice said that the prod­uct will soon re­place the in­jec­tions as well as tra­di­tional in­halers for pa­tients with con­di­tions such as di­a­betes, can­cer, asthma and cys­tic fi­bro­sis. The prod­uct de­vel­op­ers fur­ther add that it is too early to say what the price of the prod­uct will be, but they hope it to be priced be­low USD50. Ide­ally, with the new ver­sion that’s af­ford­able enough, their de­mand in de­vel­op­ing na­tions such as In­dia, Africa and oth­ers, where dis­eases are of­ten spread through re­use of non­ster­ilised nee­dles, would in­crease.

r&D in drug pow­der in­halers strength­ens

Pul­monary as well as nasal de­liv­ery is a rapidly grow­ing field. Growth in this seg­ment is par­tic­u­larly driven by the dom­i­nance of sev­eral chronic ob­struc­tive dis­eases, par­tic­u­larly in de­vel­op­ing coun­tries such as In­dia, Africa and oth­ers. Fur­ther­more, the dry pow­der in­haler tech­nol­ogy that uses en­gi­neered par­ti­cles has also be­come the most pre­ferred ap­proach, when it comes to in­hala­tion for­mu­la­tion, over other aerosols as well as dry-pow­der tech­nolo­gies.

A com­pany named “Cap­sugel’s Dosage Form So­lu­tions” shot to fame when it made a huge in­vest­ment in two im­por­tant com­po­nents re­quired to ad­min­is­ter an in­hala­tion dosage form for its end-users. The com­pany’s in­hala­tion for­mu­la­tion as well as process de­sign ap­plies a par­ti­cle – en­gi­neer­ing pro­duc­tion plat­form. An­other at­trac­tion is the man­u­fac­turer’s full range of en­gi­neered dry pow­der in­haler cap­sule. Cap­sugel’s prod­uct is in its Phase 3 clin­i­cal man­u­fac­tur­ing scales. They are also op­er­at­ing with equip­ment mak­ers to de­sign fin­ished equip­ment as well as fur­ther op­ti­mise the so­lu­tion. Such prod­ucts will cre­ate new op­por­tu­ni­ties for many COPD

and asthma de­vices mar­ket play­ers.

Metered dose in­halers seg­ment wit­nesses B2B deals

The metered dose in­haler seg­ment has seen ma­jor busi­ness to busi­ness deals. Pro­pel­ler Health part­nered with Ap­tar Pharma, a global drug de­liv­ery sys­tems provider. Un­der the terms of the agree­ment, Pro­pel­ler and Ap­tar will jointly de­velop the world’s first dig­i­tal, con­nected metered dose in­haler with an in­te­grated sen­sor and a novel elec­tronic dose counter. The de­vice is cur­rently avail­able for li­cens­ing and is ex­pected to en­ter clin­i­cal stud­ies later this year. Pro­pel­ler Health also an­nounced new com­mer­cial part­ner­ships with Hu­mana, whose em­ploy­ees are par­tic­i­pat­ing in the AIR Louisville pro­gramme, and with AMC Health, which will use Pro­pel­ler to power its care man­age­ment pro­grammes for com­plex COPD pa­tients. The in­vestor took this bold step to be­come the first to the mar­ket con­nected, in­te­grated metered dose in­haler com­pany. Com­ment­ing on the re­cent de­vel­op­ment, David Van Sickle, the Chief Ex­ec­u­tive Of­fi­cer at the Pro­pel­ler, said “Pa­tients and physi­cians de­serve bet­ter de­signed in­halers that are eas­ier to use and that help them suc­cess­fully treat their chronic res­pi­ra­tory dis­ease.” Sickle fur­ther ex­plained, “We are ex­cited to work with Ap­tar to bring im­por­tant dig­i­tal in­no­va­tion to res­pi­ra­tory drug de­liv­ery. We ex­pect our con­nected in­haler to be­come the cor­ner­stone for a plat­form of dig­i­tal pro­grams that will sup­port and en­cour­age bet­ter man­age­ment of and qual­ity of life with chronic res­pi­ra­tory dis­ease. To­gether I be­lieve we have the scale and ex­per­tise to im­pact mil­lions of pa­tients with asthma and COPD around the world.”

ul­tra­sonic neb­u­liser set to rev­o­lu­tionise the COPD and asthma de­vices mar­ket

Pocket–size or small ul­tra­sonic ne­bu­lis­ers ap­ply­ing a novel noz­zle that can en­hance in­halers are wit­ness­ing higher de­mand. In­dus­try ex­perts be­lieve that in­hala­tion has opened new routes for the non-in­va­sive drug de­liv­ery tech­niques, both in lo­cal as well as sys­tem­atic ap­pli­ca­tions. Be­sides this, con­trol over the par­ti­cle size and out­put is play­ing a crit­i­cal part in en­sur­ing the ef­fi­ciency and ef­fec­tive­ness of the ex­pen­sive drug de­liv­ery, which has caught the at­ten­tion of var­i­ous sci­en­tists and re­searchers.

A group of in­no­va­tors from the “Depart­ment of Elec­tri­cal En­gi­neer­ing and Com­puter Sci­ence” at the re­puted Univer­sity of Cal­i­for­nia has in­vented novel equip­ment for in­hala­tion drug de­liv­ery, which ful­fils the re­quire­ments un­met by ex­ist­ing com­mer­cial de­vices. This is a clear in­di­ca­tion that the fu­ture of the COPD and asthma de­vices mar­ket will re­main ro­bust in the years to come.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.